# A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs

Study · id `cardio:ct-nct07018453` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07018453](<https://clinicaltrials.gov/study/NCT07018453>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07018453

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 173 participants.

## Technical summary

Registry record NCT07018453. Randomized; no masking; primary purpose treatment. Start 2025-07-16 (actual); primary completion 2026-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 173 participants (enrolled count; ClinicalTrials.gov record NCT07018453, source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)
- Started: 2025-07-16 (actual) (ClinicalTrials.gov record NCT07018453, source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)
- Primary completion: 2026-02 (anticipated) (ClinicalTrials.gov record NCT07018453, source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)
- Completion: 2026-05 (anticipated) (ClinicalTrials.gov record NCT07018453, source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07018453, source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07018453-2025-11-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study Comparing SHR-3167 and Insulin Degludec in Type 2 Diabetic Subjects Treated With Basal Insulin With or Without Oral Antidiabetic Drugs
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): SHR-3167
- Intervention (Drug): Insulin Degludec
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: b79bd573757c7651606f620d420c417e0deb77a488b2ebae643a4a96d7ae1e5e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
